Loading…
Arresting Developments in Biased Signaling
The ability to design ‘biased’ drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differe...
Saved in:
| Published in: | Trends in pharmacological sciences (Regular ed.) 2020-06, Vol.41 (6), p.387-389 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c356t-977cb3373c98ab9a15a9bfdd5b192e3673269f3a0d8111d6021730c3108e72b43 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c356t-977cb3373c98ab9a15a9bfdd5b192e3673269f3a0d8111d6021730c3108e72b43 |
| container_end_page | 389 |
| container_issue | 6 |
| container_start_page | 387 |
| container_title | Trends in pharmacological sciences (Regular ed.) |
| container_volume | 41 |
| creator | Yoo, Sungsoo M. Bhardwaj, Anshul Benovic, Jeffrey L. |
| description | The ability to design ‘biased’ drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differences in the β1-adrenoceptor in complex with β-arrestin 1 versus a G protein-mimicking nanobody. |
| doi_str_mv | 10.1016/j.tips.2020.04.003 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2398162442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165614720300894</els_id><sourcerecordid>2398162442</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-977cb3373c98ab9a15a9bfdd5b192e3673269f3a0d8111d6021730c3108e72b43</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAyxQlwgpwfYkdiKxKeUpVWIBrC3HnlSu8sJOK_H3JGphyWo2Z67uPYRcMhozysTtJu5dF2JOOY1pElMKR2TKMgkRSEiPyXSA0kiwRE7IWQgbOhDA2SmZAAfBIWFTcrPwHkPvmvX8AXdYtV2NTR_mrpnfOx3Qzt_dutHVAJyTk1JXAS8Od0Y-nx4_li_R6u35dblYRQZS0Ue5lKaAoYHJM13kmqU6L0pr04LlHEFI4CIvQVObMcasoJxJoAYYzVDyIoEZud7ndr792g7lVO2CwarSDbbboDjkGRM8SfiA8j1qfBuCx1J13tXafytG1ehIbdToSI2OFE3UaGBGrg7526JG-_fyK2UA7vYADit3Dr0KxmFj0DqPple2df_l_wDYrHW0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398162442</pqid></control><display><type>article</type><title>Arresting Developments in Biased Signaling</title><source>ScienceDirect Journals</source><creator>Yoo, Sungsoo M. ; Bhardwaj, Anshul ; Benovic, Jeffrey L.</creator><creatorcontrib>Yoo, Sungsoo M. ; Bhardwaj, Anshul ; Benovic, Jeffrey L.</creatorcontrib><description>The ability to design ‘biased’ drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differences in the β1-adrenoceptor in complex with β-arrestin 1 versus a G protein-mimicking nanobody.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/j.tips.2020.04.003</identifier><identifier>PMID: 32362341</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; arrestin ; beta-Arrestin 1 - chemistry ; beta-Arrestin 1 - metabolism ; Biomimetic Materials - chemistry ; cryo-EM ; G protein-coupled receptor ; Humans ; Models, Molecular ; Molecular Targeted Therapy ; Receptors, Adrenergic, beta-1 - chemistry ; Receptors, Adrenergic, beta-1 - metabolism ; Receptors, G-Protein-Coupled - agonists ; Receptors, G-Protein-Coupled - chemistry ; Receptors, G-Protein-Coupled - metabolism ; Signal Transduction - drug effects ; Single-Domain Antibodies - chemistry</subject><ispartof>Trends in pharmacological sciences (Regular ed.), 2020-06, Vol.41 (6), p.387-389</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-977cb3373c98ab9a15a9bfdd5b192e3673269f3a0d8111d6021730c3108e72b43</citedby><cites>FETCH-LOGICAL-c356t-977cb3373c98ab9a15a9bfdd5b192e3673269f3a0d8111d6021730c3108e72b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32362341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoo, Sungsoo M.</creatorcontrib><creatorcontrib>Bhardwaj, Anshul</creatorcontrib><creatorcontrib>Benovic, Jeffrey L.</creatorcontrib><title>Arresting Developments in Biased Signaling</title><title>Trends in pharmacological sciences (Regular ed.)</title><addtitle>Trends Pharmacol Sci</addtitle><description>The ability to design ‘biased’ drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differences in the β1-adrenoceptor in complex with β-arrestin 1 versus a G protein-mimicking nanobody.</description><subject>Animals</subject><subject>arrestin</subject><subject>beta-Arrestin 1 - chemistry</subject><subject>beta-Arrestin 1 - metabolism</subject><subject>Biomimetic Materials - chemistry</subject><subject>cryo-EM</subject><subject>G protein-coupled receptor</subject><subject>Humans</subject><subject>Models, Molecular</subject><subject>Molecular Targeted Therapy</subject><subject>Receptors, Adrenergic, beta-1 - chemistry</subject><subject>Receptors, Adrenergic, beta-1 - metabolism</subject><subject>Receptors, G-Protein-Coupled - agonists</subject><subject>Receptors, G-Protein-Coupled - chemistry</subject><subject>Receptors, G-Protein-Coupled - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Single-Domain Antibodies - chemistry</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqXwAyxQlwgpwfYkdiKxKeUpVWIBrC3HnlSu8sJOK_H3JGphyWo2Z67uPYRcMhozysTtJu5dF2JOOY1pElMKR2TKMgkRSEiPyXSA0kiwRE7IWQgbOhDA2SmZAAfBIWFTcrPwHkPvmvX8AXdYtV2NTR_mrpnfOx3Qzt_dutHVAJyTk1JXAS8Od0Y-nx4_li_R6u35dblYRQZS0Ue5lKaAoYHJM13kmqU6L0pr04LlHEFI4CIvQVObMcasoJxJoAYYzVDyIoEZud7ndr792g7lVO2CwarSDbbboDjkGRM8SfiA8j1qfBuCx1J13tXafytG1ehIbdToSI2OFE3UaGBGrg7526JG-_fyK2UA7vYADit3Dr0KxmFj0DqPple2df_l_wDYrHW0</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Yoo, Sungsoo M.</creator><creator>Bhardwaj, Anshul</creator><creator>Benovic, Jeffrey L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202006</creationdate><title>Arresting Developments in Biased Signaling</title><author>Yoo, Sungsoo M. ; Bhardwaj, Anshul ; Benovic, Jeffrey L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-977cb3373c98ab9a15a9bfdd5b192e3673269f3a0d8111d6021730c3108e72b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>arrestin</topic><topic>beta-Arrestin 1 - chemistry</topic><topic>beta-Arrestin 1 - metabolism</topic><topic>Biomimetic Materials - chemistry</topic><topic>cryo-EM</topic><topic>G protein-coupled receptor</topic><topic>Humans</topic><topic>Models, Molecular</topic><topic>Molecular Targeted Therapy</topic><topic>Receptors, Adrenergic, beta-1 - chemistry</topic><topic>Receptors, Adrenergic, beta-1 - metabolism</topic><topic>Receptors, G-Protein-Coupled - agonists</topic><topic>Receptors, G-Protein-Coupled - chemistry</topic><topic>Receptors, G-Protein-Coupled - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Single-Domain Antibodies - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoo, Sungsoo M.</creatorcontrib><creatorcontrib>Bhardwaj, Anshul</creatorcontrib><creatorcontrib>Benovic, Jeffrey L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoo, Sungsoo M.</au><au>Bhardwaj, Anshul</au><au>Benovic, Jeffrey L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Arresting Developments in Biased Signaling</atitle><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>2020-06</date><risdate>2020</risdate><volume>41</volume><issue>6</issue><spage>387</spage><epage>389</epage><pages>387-389</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>The ability to design ‘biased’ drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differences in the β1-adrenoceptor in complex with β-arrestin 1 versus a G protein-mimicking nanobody.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32362341</pmid><doi>10.1016/j.tips.2020.04.003</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-6147 |
| ispartof | Trends in pharmacological sciences (Regular ed.), 2020-06, Vol.41 (6), p.387-389 |
| issn | 0165-6147 1873-3735 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2398162442 |
| source | ScienceDirect Journals |
| subjects | Animals arrestin beta-Arrestin 1 - chemistry beta-Arrestin 1 - metabolism Biomimetic Materials - chemistry cryo-EM G protein-coupled receptor Humans Models, Molecular Molecular Targeted Therapy Receptors, Adrenergic, beta-1 - chemistry Receptors, Adrenergic, beta-1 - metabolism Receptors, G-Protein-Coupled - agonists Receptors, G-Protein-Coupled - chemistry Receptors, G-Protein-Coupled - metabolism Signal Transduction - drug effects Single-Domain Antibodies - chemistry |
| title | Arresting Developments in Biased Signaling |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A19%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Arresting%20Developments%20in%20Biased%20Signaling&rft.jtitle=Trends%20in%20pharmacological%20sciences%20(Regular%20ed.)&rft.au=Yoo,%20Sungsoo%20M.&rft.date=2020-06&rft.volume=41&rft.issue=6&rft.spage=387&rft.epage=389&rft.pages=387-389&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/j.tips.2020.04.003&rft_dat=%3Cproquest_cross%3E2398162442%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-977cb3373c98ab9a15a9bfdd5b192e3673269f3a0d8111d6021730c3108e72b43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2398162442&rft_id=info:pmid/32362341&rfr_iscdi=true |